Analysts at RBC Capital reaffirmed 'buy' rating of XenoPort's stock, Market Beat reported. The RBC gave its rating in a research note issued on Tuesday. RBC analysts mentioned that they presently have a $10.00 price objective on the biopharmaceutical company's stock.

The biopharmaceutical company XenoPort traded down at 28.08% during midday trading on Tuesday reaching at $4.84. The company's stock had a trading volume of 16,040,672 shares.

XenoPort majorly focuses on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders.

The company last reported its quarterly earnings results on August 5th reporting ($0.39) earnings per share for the quarter, failing to meet the Zacks' consensus estimate of ($0.32) by $0.07.

Company's business revenue was up 62.3% as compared to the same quarter last year. During previous year in the same period the company earned ($0.31) earnings per share.

The company is commercializing HORIZANT Extended-Release Tablets in the US and REGNITE Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. (Astellas).

HORIZANT is used for the treatment of primary restless legs syndrome (RLS) and for the management of postherpetic neuralgia (PHN).

CEO Ronald W. Barrett sold 12,500 shares of the business's stock in a transaction that occurred on Wednesday, July 15th. Stock was sold at an average price of $7.20, for a total transaction of $90,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.